Anika Therapeutics (ANIK) Q3 2026 earnings review
Anika raises its 2026 outlook, but regulators reject Hyalofast
Anika Therapeutics — the maker of joint-pain injections and surgical implants — leaned on its legacy partner business this quarter as its direct surgical growth engine cooled and US regulators rejected a key pipeline product. Third-quarter revenue rose 10% from a year ago, and chief executive Steve Griffin nudged the bottom of the full-year sales and profit outlook higher after signing a 10-year equine distribution deal. However, by our math the updated plan still points to total revenue falling about 5% in the fourth quarter.
| Revenue | $30.6M +10% from a year ago |
|---|---|
| Gross margin | 62% 56% a year ago; 65% last quarter |
| Commercial Channel outlook | Cut to 9–13% from 12–18% previously |
| Full-year revenue outlook | Raised low end 6–10% growth (middle: 8%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the two pillars of Anika's long-term growth case — direct surgical sales and the US pipeline — both took a hit. The US Food and Drug Administration rejected the Hyalofast knee-cartilage application over its clinical data, and management cut its 2026 Commercial Channel growth forecast as elective surgeries slowed. On the positive side, third-quarter free cash flow turned positive at about $7 million by our math, and the Cingal pain study finished patient enrollment.
The question now is whether the fourth-quarter slowdown in the outlook is management's usual caution or a real drop in surgical demand and partner pricing. If the plan is just cautious, Anika will beat its fourth-quarter implied targets as it did in the third quarter; if demand and product mix are weakening, gross margin will stay below the 64% target and direct sales will stall. Fourth-quarter Commercial Channel revenue and gross margin will settle it.
🐂 Bull Case
New Ten-Year Equine Deal Lifts Partner Economics
Anika's Original Equipment Manufacturer (OEM) channel sells joint-health products through large partners like Johnson & Johnson and Boehringer Ingelheim. After two years of shrinking sales, this partner channel is growing again, up 5% from a year ago to $16.6 million in the third quarter.
In November, the joint-preservation company signed a new 10-year partnership with Boehringer Ingelheim to distribute Hyvisc, a hyaluronic acid injection for horses. The deal brings "higher transfer pricing, a royalty on end-market sales, higher contractual purchases and upfront and milestone payments". Anika also reintroduced Hyalomatrix, a wound-care product, through a new US distributor.
This contract matters because it brings $8 million in cash payments, including $4 million upfront in the first quarter of 2027, and locks in better pricing for a decade. That helped chief executive Steve Griffin lift the 2026 partner-channel growth outlook to 5%–9%, up from 0%–5%.
What to watch: the 2027 partner-channel outlook when fourth-quarter results arrive. Despite the new contract and the wound-care relaunch, the company still forecasts flat to slightly lower partner sales next year.
Third-Quarter Cash Generation Turned Positive
During the first half of 2026, Anika burned $8.4 million of free cash flow as it built up inventory and waited on customer payments. Management told investors last quarter that cash generation would turn positive in the second half.
In the third quarter, the medical-device maker delivered on that goal. By our math, subtracting six-month figures from the nine-month cash flow statement shows $8.4 million of operating cash flow and $6.7 million of free cash flow in the quarter. Cash on hand rose from $38.4 million in June to $45.0 million in September.
This turnaround matters because it shows the company's higher operating profit is finally turning into cash, even while factories keep adding safety stock. One good quarter does not settle the full-year cash question, because nine-month free cash flow is still negative $1.7 million by our math.
What to watch: fourth-quarter operating cash flow and inventory levels. Another cash-positive quarter would leave full-year free cash flow positive and prove the first-half cash drain was temporary.
Cingal Study Finishes Enrollment and Gets a Filing Window
Cingal is Anika's next-generation injection that combines hyaluronic acid with a fast-acting steroid to treat osteoarthritis knee pain. It already sells overseas, where international osteoarthritis pain sales grew 19% from a year ago in the third quarter, and the company wants US approval.
In September, Anika finished enrolling patients in the Cingal bioequivalence study, a clinical trial required by US regulators. The company is now preparing the clinical report and the manufacturing paperwork needed to file hyaluronic acid as a drug, and plans to submit its US application before the end of 2027.
With Hyalofast rejected by regulators, Cingal is now the company's main long-term US pipeline opportunity. Finishing enrollment ahead of its year-end target removes one clinical hurdle, though more than a year of manufacturing paperwork remains before filing.
What to watch: completion of the clinical study report and updates on drug-manufacturing readiness in early 2027. Any delay in the manufacturing paperwork would push the US submission past 2027.
🐻 Bear Case
FDA Rejects the Hyalofast Knee Cartilage Application
Hyalofast is a biodegradable scaffold that surgeons use to repair damaged knee cartilage, and it was supposed to be Anika's next big US product launch. Last quarter, the company removed $3 million of expected 2027 US Hyalofast sales from its long-term forecast while it answered questions from the US Food and Drug Administration (FDA).
In October, the FDA formally notified Anika that its pre-market approval application for Hyalofast is not approvable, "primarily based on the clinical data included in the submission". The phase 3 trial had previously missed its main statistical goals. Anika said it still believes in the product and will talk with the agency about what extra clinical evidence it needs.
This rejection matters because a clinical data shortfall cannot be fixed with simple paperwork. Running a new clinical trial or gathering extra patient data takes years and costs money, so Hyalofast will not contribute to US growth in the foreseeable future.
What to watch: the outcome of Anika's regulatory discussions with the FDA over the next two quarters. If the agency requires a new clinical trial, management may have to shelve the US launch or commit millions in fresh research spending.
Direct Sales Slowed as Elective Surgeries Cooled
Anika's Commercial Channel sells regenerative implants and international pain injections directly to hospitals and distributors, and it is supposed to be the company's fast-growing engine. Chief executive Steve Griffin said third-quarter progress "reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations".
In the same release, the company cut its 2026 growth forecast for this direct channel from 12%–18% down to 9%–13%, blaming "a slower than anticipated third quarter elective surgery market". Integrity, its tendon-repair patch, grew more than 30% from a year ago and reached $7.5 million in sales over the past 12 months, aided by new surgical tools launched in September.
- Commercial Channel revenue: $14.0 million in Q3, up 17% from a year ago and up 15% over nine months
- New 2026 Commercial outlook: 9% to 13% growth, down from 12% to 18% previously
- Fourth-quarter Commercial growth: about 0.6% from a year ago at the middle of the range, by our math
The cut contradicts the confident headline because nine-month sales in the channel are already up 15%. For full-year growth to land at the 11% midpoint, fourth-quarter direct sales must slow to almost zero growth from a year ago.
What to watch: fourth-quarter Commercial Channel revenue against the $13.3 million implied by the middle of the full-year plan. A flat reading would show that slower elective surgeries are hurting implant demand more than new product sizes are helping.
Gross Margin Slipped Below the 64% Target
Faster factory output and higher-margin products lifted Anika's gross margin from 56% a year ago to 64% in the first quarter and 65% in the second. On last quarter's call, Griffin told investors that the company expected to maintain a 64% gross margin through the second half of the year.
In the third quarter, GAAP gross margin came in at 61.6% (reported as 62%). Cost of revenue — the expense of making the products — fell 5.6 percentage points of revenue from a year ago to 38.4%, helped by higher factory output and FDA approval of a new sterile process. However, shipping the first units of Hyalomatrix, a lower-margin wound product sold through a partner, pulled the margin down from the second quarter.
This dip matters because it shows how sensitive Anika's profitability is to product mix. When partner sales grow faster than direct surgical sales, the overall gross margin steps down even when the factories run well.
What to watch: fourth-quarter gross margin. A rebound to 64% would show the third-quarter dip was just initial wound-care shipments, while another reading near 62% would reset the margin baseline lower.
Risks this quarter didn't answer
Several standing concerns about customer reliance, product economics and accounting adjustments got no new detail in the earnings release.
- Johnson & Johnson pricing and volume split: not in the release; the quarterly filing's revenue footnote and management discussion will show how much US price erosion offset volume gains.
- Standalone Integrity quarterly figures: the release gave 12-month sales ($7.5 million) and nine-month growth (37%), but omitted quarterly dollars, procedure counts and surgeon users; the conference call may provide them.
- Tax-effected non-GAAP add-backs: for the nine months, the adjusted net income table adds back $14.8 million of stock-based compensation and $2.9 million of severance after tax, which again exceeds the pre-tax GAAP charges of $12.7 million and $2.5 million.
💲 Other KPIs
Inventories rose 61.6% from the end of 2025 and 86.4% from a year ago, far outpacing the 10.0% rise in quarterly revenue. Anika said it is "increasing production and building safety stock to support future growth" after output on its main cross-link manufacturing line rose more than 50% above 2022 levels.
Total operating expenses rose 3.9% from a year ago, slower than the 10.0% revenue gain. Selling, general and administrative costs — overhead and sales pay — fell 4.6 percentage points of revenue to 38.1% after first-half layoffs. Research and development spending rose 0.8 percentage points of revenue to 25.8% on clinical trial work.
Weighted average diluted shares fell 7.2% from a year ago after the medical-device group spent $9.5 million on buybacks in the first half of 2026. The company did not repurchase shares in the third quarter, and quarterly stock-based compensation — employee pay in shares — nearly doubled from a year ago to $4.2 million.
🔮 Guidance
Raised. Anika lifted the bottom of its full-year revenue growth plan by 1 percentage point, moving the middle of the range to 8.0% growth. Because nine-month sales are already up 12.9%, by our math the plan leaves fourth-quarter revenue falling about 5.2% from a year ago to $29.0 million. It is the second raise this year, smaller than last quarter's 2.5-point increase.
Raised. The partner-channel outlook moved up 4.5 percentage points at the middle of the range to 7.0% growth, supported by Hyvisc demand and the wound-care relaunch. With nine-month partner sales up 11.1%, by our math the new range still points to a 4.3% drop from a year ago in the fourth quarter against a tough comparison.
Cut. Management lowered its direct-channel growth plan by 4 percentage points at the middle of the range to 11.0%, citing slower elective surgery volumes in the summer. Because nine-month direct sales grew 15.3%, by our math the middle of the new range leaves fourth-quarter revenue up just 0.6% from a year ago.
Raised. The bottom of the full-year profit margin range excluding one-offs rose 2 percentage points, putting the middle of the range at 16.0%. Nine-month margin stands at 17.8% after a 16.7% third quarter. By our math, the full-year midpoint implies a 10.4% margin in the fourth quarter. This is the second raise this year, following a 7.5-point jump last quarter.
Unchanged. The company kept its 2027 total revenue forecast at 0% to 5% growth, a range it first set last quarter after stripping out unapproved products like Hyalofast. At the 2.5% midpoint, growth next year would slow from the 8.0% pace planned for 2026.
Unchanged. Anika still expects partner-channel sales to be flat to slightly down in 2027, even after signing the new 10-year Boehringer Ingelheim equine contract and reintroducing its wound-care product in the US.
Unchanged. Management kept next year's direct-channel growth target at 5% to 15%. The 10.0% midpoint is in line with the lowered 11.0% midpoint now planned for 2026.
❓ Key Questions
What will the FDA require for Hyalofast approval?
The FDA rejected the Hyalofast application based on its clinical data. Investors need to know if the agency wants a new phase 3 trial, how much that would cost, and whether Anika will fund it.
Why does the Commercial outlook imply flat fourth-quarter sales?
Nine-month Commercial Channel sales grew 15%, yet the cut 2026 outlook of 9%–13% implies fourth-quarter sales will barely grow from a year ago. Management has not said whether distributor orders or surgical volumes are driving that slowdown.
Why did nine-month tax-effected add-backs exceed GAAP expenses?
In the nine-month non-GAAP reconciliation, tax-effected stock-based compensation ($14.8 million) and severance ($2.9 million) are larger than the pre-tax GAAP charges ($12.7 million and $2.5 million). Taxes should reduce add-backs, not enlarge them.
Why is the 2027 OEM outlook still flat to lower?
Anika just signed a 10-year Hyvisc contract with higher pricing, royalties and a $4 million upfront payment in early 2027, plus a US wound-care relaunch. Why do those additions not lift 2027 partner-channel sales?